The association between glycemic variability and diabetic cardiovascular autonomic neuropathy in patients with type 2 diabetes

BackgroundIt is presently unclear whether glycemic variability is associated with diabetic cardiovascular autonomic neuropathy (CAN). The aim of this study was to examine whether short- and/or long-term glycemic variability (GV) contribute to CAN.MethodsA total of 110 patients with type 2 diabetes who underwent three-day continuous glucose monitoring (CGM) completed five standardized autonomic neuropathy tests. Short-term GV was measured by the standard deviation (SD), coefficient of variation (CV) of glucose, and the mean amplitude of glycemic excursions (MAGE) in CGM. HbA1c variability was calculated from the intrapersonal SD, adjusted SD, and CV of serial HbA1c over 2-year period. CAN was defined as the presence of at least two abnormal parasympathetic function tests. The severity of CAN was evaluated by total scores of five autonomic function tests.ResultsIn univariate analysis, not only SD and CV in CGM but also all parameters of HbA1c variability were significantly higher in the patients with CAN (n = 47, 42.7 %) than in those without CAN. In multivariate analysis, CV (Odds ratio [OR] 1.07, 95 % confidence interval [CI] 1.01–1.13; p = 0.033), but neither SD nor MAGE in CGM, independently correlated with the presence of CAN. All parameters of HbA1c variability, such as SD of HbA1c (OR 12.10 [95 % CI 2.29–63.94], p = 0.003), adjusted SD of HbA1c (OR 17.02 [95 % CI 2.66–108.86], p = 0.003), and log CV of HbA1c (OR 24.00 [95 % CI 3.09–186.48], p = 0.002), were significantly associated with the presence of CAN. The patients with higher HbA1c variability had an increased risk of advanced CAN.ConclusionCV in CGM and all parameters of HbA1c variability were independently associated with the presence of CAN in patients with inadequately controlled type 2 diabetes requiring CGM.

[1]  C. Jung,et al.  Association of serum adipocytokine levels with cardiac autonomic neuropathy in type 2 diabetic patients , 2012, Cardiovascular Diabetology.

[2]  A. Rigby,et al.  A1C Variability and the Risk of Microvascular Complications in Type 1 Diabetes , 2008, Diabetes Care.

[3]  S. Shin,et al.  HbA1c variability is associated with microalbuminuria development in type 2 diabetes: a 7-year prospective cohort study , 2012, Diabetologia.

[4]  R. Freeman,et al.  Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management , 2011, Diabetes/metabolism research and reviews.

[5]  Frits Holleman,et al.  Glucose variability; does it matter? , 2010, Endocrine reviews.

[6]  Dan Ziegler,et al.  Diabetic neuropathies: a statement by the American Diabetes Association. , 2005, Diabetes care.

[7]  S. Chon.  How Can We Easily Measure Glycemic Variability in Diabetes Mellitus? , 2015, Diabetes & metabolism journal.

[8]  J. Škrha,et al.  Glycemic variability is higher in type 1 diabetes patients with microvascular complications irrespective of glycemic control. , 2014, Diabetes technology & therapeutics.

[9]  J. DeVries,et al.  Glucose fluctuations and activation of oxidative stress in patients with type 1 diabetes , 2007, Diabetologia.

[10]  E. Kilpatrick,et al.  The rise and fall of HbA1c as a risk marker for diabetes complications , 2012, Diabetologia.

[11]  J. Hans DeVries,et al.  Glucose Variability: Where It Is Important and How to Measure It , 2013, Diabetes.

[12]  D. Ewing,et al.  Heart rate variability. The International Federation of Clinical Neurophysiology. , 1999, Electroencephalography and clinical neurophysiology. Supplement.

[13]  G. Zoppini,et al.  Hemoglobin A1c variability as an independent correlate of cardiovascular disease in patients with type 2 diabetes: a cross-sectional analysis of the Renal Insufficiency and Cardiovascular Events (RIACE) Italian Multicenter Study , 2013, Cardiovascular Diabetology.

[14]  T. Ninomiya,et al.  Thresholds of various glycemic measures for diagnosing diabetes based on prevalence of retinopathy in community-dwelling Japanese subjects: the Hisayama Study , 2014, Cardiovascular Diabetology.

[15]  Merlin C. Thomas,et al.  Mechanisms of Disease: pathway-selective insulin resistance and microvascular complications of diabetes , 2005, Nature Clinical Practice Endocrinology &Metabolism.

[16]  Paola Palazzo,et al.  Impact of Glycemic and Blood Pressure Variability on Surrogate Measures of Cardiovascular Outcomes in Type 2 Diabetic Patients , 2011, Diabetes Care.

[17]  Michael Brownlee,et al.  The Effect of Glucose Variability on the Risk of Microvascular Complications in Type 1 Diabetes , 2007, Diabetes Care.

[18]  T. Ninomiya,et al.  Haemoglobin A1c even within non-diabetic level is a predictor of cardiovascular disease in a general Japanese population: the Hisayama Study , 2013, Cardiovascular Diabetology.

[19]  R. Esper,et al.  Endothelial dysfunction: a comprehensive appraisal , 2006, Cardiovascular diabetology.

[20]  D. Ewing,et al.  The Value of Cardiovascular Autonomic Function Tests: 10 Years Experience in Diabetes , 1985, Diabetes Care.

[21]  S. Liatis,et al.  Relationship between Autonomic Nervous System Function and Continuous Interstitial Glucose Measurement in Patients with Type 2 Diabetes , 2014, Journal of diabetes research.

[22]  Sang-Man Jin,et al.  Clinical factors associated with absolute and relative measures of glycemic variability determined by continuous glucose monitoring: an analysis of 480 subjects. , 2014, Diabetes research and clinical practice.

[23]  Eckhard Salzsieder,et al.  The use of a computer program to calculate the mean amplitude of glycemic excursions. , 2011, Diabetes technology & therapeutics.

[24]  K. Griendling,et al.  Serial Review : The Role of Oxidative Stress in Diabetes mellitus Serial Review , 2006 .

[25]  A. Ceriello,et al.  Constant and intermittent high glucose enhances endothelial cell apoptosis through mitochondrial superoxide overproduction , 2006, Diabetes/metabolism research and reviews.

[26]  B. Feng,et al.  Atorvastatin inhibits the expression of RAGE induced by advanced glycation end products on aortas in healthy Sprague–Dawley rats , 2014, Diabetology & Metabolic Syndrome.

[27]  The Relationship of Glycemic Exposure (HbA1c) to the Risk of Development and Progression of Retinopathy in the Diabetes Control and Complications Trial , 1995, Diabetes.

[28]  A. Rigby,et al.  Effect of Glucose Variability on the Long-Term Risk of Microvascular Complications in Type 1 Diabetes , 2009, Diabetes Care.

[29]  Xiao-hua Wang,et al.  The relationship between glycemic variability and diabetic peripheral neuropathy in type 2 diabetes with well-controlled HbA1c , 2014, Diabetology & Metabolic Syndrome.

[30]  H. Sone,et al.  HbA1c variability and the development of microalbuminuria in type 2 diabetes: Tsukuba Kawai Diabetes Registry 2 , 2012, Diabetologia.

[31]  C. Forsblom,et al.  HbA1c variability is associated with an increased risk of retinopathy requiring laser treatment in type 1 diabetes , 2013, Diabetologia.

[32]  A. Huffelen,et al.  Is the Corrected QT Interval a Reliable Indicator of the Severity of Diabetic Autonomic Neuropathy? , 1993, Diabetes Care.

[33]  Giuseppe Pugliese,et al.  HbA1c Variability as an Independent Correlate of Nephropathy, but Not Retinopathy, in Patients With Type 2 Diabetes , 2013, Diabetes Care.

[34]  A. Vinik,et al.  Diabetic Cardiovascular Autonomic Neuropathy , 2007, Circulation.

[35]  A. Rigby,et al.  Glucose variability does not contribute to the development of peripheral and autonomic neuropathy in type 1 diabetes: data from the DCCT , 2009, Diabetologia.

[36]  J. Joung,et al.  Association between the extent of urinary albumin excretion and glycaemic variability indices measured by continuous glucose monitoring , 2015, Diabetic medicine : a journal of the British Diabetic Association.

[37]  G. Krishnarajah,et al.  Glycaemic variability and complications in patients with diabetes mellitus: evidence from a systematic review of the literature , 2010, Diabetes, obesity & metabolism.

[38]  J. Fleischer.  Diabetic Autonomic Imbalance and Glycemic Variability , 2012, Journal of diabetes science and technology.

[39]  Antonio Ceriello,et al.  Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: the role of protein kinase C and NAD(P)H-oxidase activation. , 2003, Diabetes.

[40]  M. Orsini Federici,et al.  Assessment of the association between glycemic variability and diabetes-related complications in type 1 and type 2 diabetes. , 2014, Diabetes research and clinical practice.

[41]  Xilin Yang,et al.  Risk association of HbA1c variability with chronic kidney disease and cardiovascular disease in type 2 diabetes: prospective analysis of the Hong Kong Diabetes Registry , 2013, Diabetes/metabolism research and reviews.

[42]  J. P. O’Hare,et al.  The prevalence of autonomic neuropathy in insulin-dependent diabetes mellitus: a controlled study based on heart rate variability. , 1986, The Quarterly journal of medicine.